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Purpose: To identify survival predictors and to design a
prognostic score useful for distinguishing risk groups in immu-
nocompetent patients with primary CNS lymphomas (PCNSL).
Patients and Methods: The prognostic role of patient-,
lymphoma-, and treatment-related variables was analyzed
in a multicenter series of 378 PCNSL patients treated at 23
cancer centers from five different countries.
Results: Age more than 60 years, performance status
(PS) more than 1, elevated lactate dehydrogenase (LDH)
serum level, high CSF protein concentration, and involve-
ment of deep regions of the brain (periventricular regions,
basal ganglia, brainstem, and/or cerebellum) were signifi-
cantly and independently associated with a worse survival.
These five variables were used to design a prognostic score.
Each variable was assigned a value of either 0, if favorable,
or 1, if unfavorable. The values were then added together to
arrive at a final score, which was tested in 105 assessable
patients for which complete data of all five variables were
available. The 2-year overall survival (OS)  SD was 80% 
8%, 48%  7%, and 15%  7% (P  .00001) for patients with
zero to one, two to three, and four to five unfavorable fea-
tures, respectively. The prognostic role of this score was con-
firmed by limiting analysis to assessable patients treated with
high-dose methotrexate-based chemotherapy (2-year OS 
SD: 85%  8%, 57%  8%, and 24%  11%; P  .0004).
Conclusion: Age, PS, LDH serum level, CSF protein con-
centration, and involvement of deep structures of the brain
were independent predictors of survival. A prognostic score
including these five parameters seems advisable in distin-
guishing different risk groups in PCNSL patients. The pro-
posed score and its relevance in therapeutic decision de-
serve to be validated in further studies.
J Clin Oncol 21:266-272. © 2003 by American
Society of Clinical Oncology.
IN SERIES investigating the management of primary CNSlymphomas (PCNSL), the differences in outcome observed
among various treatment options have been attributed to an
inhomogeneous distribution of prognostic indicators rather than
the real efficacy of therapeutic strategies.1 Indeed, apart from age
and performance status (PS), which are universally accepted
prognostic factors,1,2 no other parameters influencing outcome
have been consistently identified.
Efforts to identify predictors of response and survival in
PCNSL have produced isolated observations in small series,
which have not been confirmed in successive studies. The
characterization of predictors of response and survival using
large series may allow us to identify different patient risk groups,
facilitate the comparative analysis of prospective trials, and
define stratification criteria for future trials. In this study,
predictors of response and survival were analyzed in an interna-
tional multicenter retrospective series of 378 immunocompetent
patients with PCNSL. A prognostic score resulting from the
combined analysis of the independent variables is proposed in
light of its potential clinical relevance.
PATIENTS AND METHODS
Study Group
A questionnaire requesting information about patient characteristics,
clinical presentation, diagnosis, staging, planned and actually performed
treatment, objective response, site and date of relapse, second-line treatment,
neurotoxicity, and survival was sent to 48 centers referring to the Interna-
tional Extranodal Lymphoma Study Group. Report forms were submitted to
at least one clinician (hematologist or oncologist) and one pathologist per
center. Only patient cases diagnosed and treated at the participating institu-
tions that fulfilled the following criteria were selected: (1) histologic or
cytologic diagnosis of lymphoma; (2) disease localized exclusively in the
brain, cranial nerves, meninges, or eyes; and (3) no evidence of human
immunodeficiency virus-1 infection (negative serologic tests and absence of
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epidemiologic risk, opportunistic infections, or lymphopenia for patients
diagnosed in the early 1980s) or other immunodeficiencies. The history of a
prior cancer was not an exclusion criterion.
Thirty-four out of 48 centers responded (response rate, 71%); 11 centers
did not register patients in the study. Therefore, data of 378 PCNSL patients
diagnosed between 1980 and 1999 were collected by 23 cancer centers (48%
of responding centers) from five different countries.
Questionnaire data were verified during a consensus meeting held at
Ascona, Switzerland, on February 2000; equivocal submitted information
was subsequently analyzed until consensus for every single patient case was
reached. Each institution carried out a radiologic material review. Clinical
staging work-up included at least total-body computed tomography scan and
bone marrow biopsy. Staging procedures included slit-lamp examination of
the eyes in 170 patients (45%) and CSF cytology examination in 241 patients
(64%). The cutoff for normal CSF protein concentration was 45 mg/dL in
patients  60 years old and 60 mg/dL in patients more than 60 years old.3
PS was defined according to the Eastern Cooperative Oncology Group
(ECOG) criteria. Histologic sample was obtained by stereotactic biopsy in
276 patients (72%), surgical resection in 86 patients (23%; total resection in
44 patients, subtotal in 42 patients), CSF cytology examination in 14 patients
(4%), and vitrectomy and autopsy in one patient each ( 1%).
Therapeutic Management
Therapeutic data were available from 370 patients. Planned treatment was
radiotherapy (RT) alone in 98 patients (26%), RT followed by chemotherapy
(CHT; RT3 CHT) in 36 patients (10%), CHT alone in 32 patients (9%), and
CHT followed by RT (CHT 3 RT) in 197 patients (53%). Seven patients
(2%) did not receive any treatment. It is noteworthy that five patients who
were planned to receive primary RT did not receive any treatment, whereas
61 patients who were planned to receive CHT 3 RT were not irradiated
because of progressive disease (n  25), early relapse (n  11), toxic death
(n  15), refusal (n  6), unrelated death (n  1), or because they were lost
to follow-up (n  3).
Methotrexate (MTX) was the most commonly used drug (n  169),
followed by alkylating agents (n  146, including procarbazine, thiotepa,
cyclophosphamide, and nitrosoureas), high-dose (HD) cytarabine (n  128),
and anthracyclines (n 117). MTX was administered at a dose 3 g/m2 per
course in 126 patients (75%). CHT regimen was alkylating agents alone in 25
patients, cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) or CHOP-like regimens in 43 patients, HD cytarabine-based
regimen in 11 patients, HD-MTX alone in 17 patients, HD-MTX plus
alkylating agents in 23 patients, HD-MTX plus CHOP-like regimens in 24
patients, HD-MTX plus HD cytarabine in 34 patients, and HD-MTX plus HD
cytarabine plus alkylating agent plus anthracycline in 67 patients. Other
regimens were used in 16 patients. Intrathecal CHT was used in 109 patients
and consisted of MTX in 61 patients, cytarabine in four patients, and both in
44 patients. RT was administered to the whole brain with a dose ( SD) of
42  7 Gy in patients treated with primary RT and 34  7 Gy in CHT 3
RT patients, followed or not by a tumor-bed boost; tumor-bed dose was 46
9 and 45  8 Gy, respectively. A more thorough description of variable
distribution among therapeutic subgroups and therapeutic outcome has been
recently published.4
Statistical Considerations
Response rates and clinical characteristics of the different groups of
patients were compared using the 2 test or the Fisher’s exact test for
categorical variables, according to the sample size. Objective response was
defined according to the World Health Organization criteria; overall response
rate included complete remission, continued complete remission (ie, patients
with no measurable disease after surgical resection), and partial response.
Survival curves were generated by the Kaplan-Meier method. Overall
survival (OS) was calculated from the date of histologic diagnosis to death
or last date of follow-up, whereas failure-free survival (FFS) was calculated
from the first day of treatment to relapse, progression, or death, or to last date
of follow-up. Impact on survival of clinical and therapeutic variables was
evaluated by comparing the survival curves using the log-rank test. Com-
parison of the therapeutic variables was performed on an intent-to-treat basis;
each patient was assigned to a therapeutic group according to the planned
first-line treatment.
The independent prognostic value of variables was analyzed using the Cox
proportional hazard model. The year of diagnosis was included as a
continuous variable in the multivariate analysis to rule out the possibility that
modern medical management could have influenced outcome more than the
treatment itself. All of the probability values were two-sided.
RESULTS
Patient Characteristics
The main patient characteristics are listed in Table 1. The
median age of the 378 patients was 61 years (range, 14 to 85
years), and 222 patients (58%) had an ECOG PS more than 1. An
elevated lactate dehydrogenase (LDH) serum level was detected
in 69 (35%) of the 195 patients assessed. Deep structures of the
brain, that is periventricular regions, basal ganglia, corpus
callosum, brainstem, and/or cerebellum, were involved in 136
patients (36%). Lymphomatous cells were found in 38 (16%) of
the 241 patients assessed by CSF cytology examination. A
higher proportion of patients (82 of 134, 61%) had an elevated
concentration of CSF protein.








Age  70 years 52 14





Not specified 39 10






T cell 8 2
Systemic symptoms 7 2
LDH ratio  1† 69/195 35
Ocular disease† 22/170 13
Positive CSF cytology examination† 38/241 16
High CSF protein level† 82/134 61
Multiple lesions 130 34
Involvement of deep structures‡ 136 36
Site of disease
Frontal lobe 166 44
Parietal lobe 50 13
Temporal lobe 52 14
Occipital lobe 24 6
Basal ganglia 104 28
Brain stem 21 6
Cerebellum 23 6
Meninges 39 10
Cranial nerves 3  1
*Histotype was defined according to the Working Formulation Classification.
†Relationship between the number of positive cases and the total number of
assessed patients.
‡Involvement of deep structures of the brain, ie, basal ganglia and/or corpus
callosum and/or brain stem and/or cerebellum.
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Predictors of Response
Of the 370 assessable patients, 226 (61%) achieved an
objective response, including complete remission, continued
complete response in patients with no measurable disease after
resection, and partial response. Lymphoma remained unchanged
in 22 cases, 102 patients had progressive disease during treat-
ment, and 20 patients experienced toxic death. According to the
planned therapeutic modality, 55 patients (56%) achieved an
objective response after RT, 25 patients (69%) achieved an
objective response after RT3 CHT, 19 patients (59%) achieved
an objective response after CHT alone, and 127 patients (64%)
achieved an objective response after CHT 3 RT (P  .42).
Among the 160 patients treated with primary CHT containing
HD-MTX (CHT alone in 25 patients and CHT 3 RT in 135
patients), 111 (69%) achieved an objective response. Age, PS,
LDH serum level, use of HD-MTX, and use of HD cytarabine
were significantly correlated with overall response rate (Table 2).
Predictors of Survival
Treatment failure was experienced by 267 patients; toxic
death occurred in 20 patients, progressive disease during treat-
ment occurred in 102 patients, and relapse after response to
first-line therapy occurred in 145 patients (relapse rate, 64%; 145
of 226 responders). The median FFS time was 9 months, with a
2-year FFS rate  SD of 32%  2%. One hundred sixteen
patients are alive (105 with no evidence of disease [NED]), with
a median follow-up of 24 months (range, 2 to 174 months) and
a 2-year OS rate  SD of 37%  2%. The causes of death (n 
254) were lymphoma in 221 patients, toxic death in 20 patients,
neurologic deterioration in three patients, unrelated causes while
NED in seven patients, and unknown causes while NED in three
patients. In the group treated with HD-MTX–based CHT  RT,
90 patients experienced a treatment failure, with a median FFS
time of 12 months and a 2-year FFS rate  SD of 46%  4%.
Seventy-six patients treated with HD-MTX are alive (71 NED),
with a median follow-up of 26 months (range, 2 to 174 months)
and a 2-year OS rate  SD of 52%  4%.
Among the variables tested, age 60 years (2-year OS rate
SD, 46%  3% v 29%  3%; P  .00006), ECOG PS less than
2 (50%  5% v 31%  3%; P  .00001), normal LDH level
(49%  4% v 29%  5%; P  .008), normal CSF protein
concentration (61%  7% v 39%  5%; P  .003), and absence
of involvement of deep regions of the brain (42%  3% v 28%
 4%; P  .0006) were significantly associated with a better
survival. Multivariate analysis adjusted by the main prognostic
factors (Table 3) showed an independent association between OS
and age, PS, LDH serum level, CSF protein concentration,
involvement of the deep structures of the brain, planned treat-
ment, and the use of HD-MTX.
Prognostic Score
The variables independently associated with survival in the
entire series were used to design a scoring system. These
variables were age ( 60 v  60 years), ECOG PS (0 to 1 v 2
to 4), LDH serum level (normal v elevated), protein CSF
concentration (normal v elevated), and involvement of the deep
structures of the brain (no v yes). Each variable was assigned a
value of either 0, if favorable, or 1, if unfavorable. The values of
these five variables were then added together to arrive at a final
score. The score was analyzed in the 105 assessable cases in
which complete data from all five variables were available. The
number of adverse features was significantly correlated to
survival, with a 2-year OS of 80%  8%, 48%  7%, and 15%
 7% (P  .00001) for patients with zero to one, two to three,
or four to five unfavorable features, respectively (Fig 1). In
addition, this score was analyzed in the 75 assessable patients
treated with HD-MTX–containing CHT. Once again, it revealed
a 2-year OS of 85%  8%, 57%  8%, and 24%  11% (P 
.0004) for patients with zero to one, two to three, or four to five
unfavorable features, respectively (Fig 2).
DISCUSSION
This study is an effort to identify patient- and disease-related
predictors of response and survival in an international retrospec-
tive series of 378 immunocompetent patients with PCNSL. This
is the second largest published PCNSL series and includes the
largest group of patients treated with primary CHT containing
HD-MTX. Age, ECOG PS, LDH serum level, CSF protein
concentration, and involvement of deep structures of the brain
were independent survival predictors in PCNSL patients. The
combined analysis of these five variables resulted in a prognostic
score that allows three different risk groups to be distinguished.
The identification of reliable and validated prognostic factors
is an important issue in PCNSL; their impact on survival has
been regarded as more important than the effect of treatment
itself.1,5 The statistical analysis conducted on small retrospective
series has not allowed the identification of parameters with an
independent predictive value, and some methodologic pitfalls
have probably affected the definition of prognostic factors in
prospective trials as well.6 In some trials, the inclusion of
patients with relapsed disease, systemic lymphoma, or histo-
logically unproven diagnosis introduced important interpreta-
tion biases, and the initial extension and location of brain
disease, CSF cytology status, and ocular disease were not
consistently analyzed.
Age and PS are the only two universally accepted prognostic
factors1,2,7-14; several other potential prognostic parameters such
as histotype,15 duration of symptoms, subtentorial localiza-
tion,11,15 and bilateral brain involvement11,12 were proposed but
failed to be confirmed in subsequent studies. In the past, some
investigators suggested that age is a factor influencing therapeu-
tic choice rather than an independent survival indicator,13
whereas a critical review of 50 published PCNSL series con-
firmed age as a powerful independent prognostic variable in 676
assessable immunocompetent patients.7 In our series, the
planned therapeutic strategy played a prognostic role indepen-
dent of age and PS (Table 3). Nevertheless, it is plausible that
within each treatment subgroup, age and PS have influenced
patient selection to receive more or less aggressive therapy,
mainly in relation to CHT combinations and doses.
In a nationwide survey conducted on 466 patients treated at 62
Japanese institutions,5 age, PS, B status, number of lesions,
meningeal disease, and LDH serum level were related to
survival. In that study, the influence of various prognostic factors
was even greater than the effect of CHT; the small proportion of
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patients treated with HD-MTX–based CHT (6.5%) could, how-
ever, explain these results. In other large comprehensive retro-
spective series, age16,17 and CSF protein level17 were indepen-
dently associated with survival. The analysis of large multicenter
retrospective series of unselected immunocompetent PCNSL
patients could be helpful in better defining predictors of survival.
However, the retrospective nature of these studies and the
prolonged observation period, during which standard of care and
diagnosis notably evolved, could introduce some interpretation
bias. In an attempt to overcome these difficulties, a consensus
Table 2. Variables Tested for Objective Response Either in the Entire Series (n  370) or in the Group of Patients Treated With Primary CHT Containing HD-MTX
(n  160)
Variables








PNo. % No. %
Age .001 .01
 60 years 187 123 66 96 72 75
 60 years 191 103 54 64 39 61
Sex .28 .09
Female 158 86 57 61 47 77
Male 220 140 63 99 64 65
ECOG PS .00003 .005
0-1 117 83 71 62 47 76
 1 222 120 54 93 62 66
Histotype .13 .74
A-C 11 8 73 4 3 75
D-K 297 168 57 119 82 67
LDH serum level .009 .01
Normal 126 86 68 80 63 79
Elevated 69 36 52 42 25 59
Systemic symptoms .99 .48
A 371 222 60 155 108 70
B 7 4 57 5 3 60
Ocular disease .64 .77
No 148 95 64 101 76 75
Yes 22 15 68 11 8 73
CSF cytology .32 .36
Negative 203 135 66 126 93 71
Positive 38 21 55 12 7 58
CSF protein level .16 .08
Normal 52 36 69 31 26 84
Elevated 82 47 57 54 36 67
No. of lesions .21 .34
Single 248 136 55 82 61 74
Multiple 130 80 62 57 38 67
Deep lesions .52 .19
No 236 147 62 88 59 67
Yes 134 79 59 49 38 78
Planned treatment .42 .53
RT 98 55 56 — —
RT 3 CHT 36 25 69 — —
CHT 32 19 59 25 15 60
CHT 3 RT 197 127 64 135 96 71
HD-MTX .008
No 91 51 56 — —
Yes 169 117 69 — —
HD cytarabine .004 .05
No 142 82 57 61 37 61
Yes 118 86 73 99 74 75
Alkylating agents .48 .33
No 70 43 61 46 30 65
Yes 194 128 66 114 81 71
Anthracycline .32 .71
No 118 74 62 72 52 72
Yes 142 94 66 88 59 67
Intrathecal CHT .27 .52
No 156 97 62 79 57 72
Yes 109 74 68 81 54 67
Abbreviation: ORR, overall response rate (complete remission, continued complete response in patients with no measurable disease after resection, and partial response).
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meeting to verify the questionnaire data was performed in this
study, and the year of diagnosis was included in multivariate
analysis to rule out the possibility that progressive changes in
medical management could have introduced a bias in evaluation
of outcome. Therapeutic results were poor in the present series
(2-year OS rate  SD, 37%  2%), which could be a result of
the use of ineffective and outdated therapeutic strategies. This
could have affected the identification of survival predictors.
However, the value of the proposed prognostic variables and
score was confirmed when analysis was limited to a group of
patients treated according to modern criteria; that is, HD-MTX–
based primary CHT with or without RT.
This study confirms the prognostic role of age and PS and
establishes the value of LDH serum level, CSF protein concen-
tration, and involvement of deep structures of the brain as
predictors of survival. LDH serum level was previously analyzed
as a part of the International Prognostic Index, without a
significant association with survival in PCNSL patients.18 In
fact, that Index did not clearly distinguish low-risk patients from
low-intermediate– and high-intermediate–risk groups.17 This
could be because two of the five parameters contained in the
International Prognostic Index (ie, stage of disease and number
of extranodal sites) have no variability in PCNSL. In this series,
a high LDH serum level was significantly associated with a
lower objective response rate and was independently related to a
worse prognosis.
As previously reported,17,19 an increased CSF protein level
was significantly associated with a lower response rate and
independently related to shorter survival. The use of CSF protein
level as well as any other CSF parameter as survival predictor is
problematic because diagnostic lumbar puncture is not feasible
in all PCNSL patients. This procedure has been considered
contraindicated in a widely variable percentage of cases, ranging
from 0%1 to 42%.20 The use of CSF variables could introduce a
bias because they can be assessed in only a selected and,
probably, favorable subgroup of patients. This selection bias has,
however, been excluded by previous studies,17,19 in which both
patients with available CSF protein levels and patients in whom
lumbar puncture was not performed at diagnosis showed a
similar survival. These results were confirmed in our series,
where lumbar puncture at diagnosis was tested as a dichotomic
variable (performed v not performed) in a multivariate analysis
adjusted for the other prognostic factors (data not shown).
Another difficulty is related to the cutoff level chosen to define
the unfavorable feature. In this series, the cutoff for normal CSF
protein concentration was 45 mg/dL in patients  60 years old
and 60 mg/dL in patients more than 60 years old,3 whereas a
cutoff of 150% of maximum normal level was previously used.17
Because the CSF protein level may be an indicator of a more
aggressive disease, the use of a more restrictive cutoff could
result in the misjudging of some high-risk patients.19 CSF
protein level may be a measure of tumor burden, involvement of
Table 3. Multivariate Analysis: Clinical and Therapeutic Variables Associated
With Survival
Variable Subgroup
Entire Series (N  370)
Odds
Ratio 95% CI P
Age Continuous variable 1.02 1.01-1.03 .0001
Sex Female/male 1.24 0.95-1.62 .11
ECOG PS 0-1/2-4 1.64 1.21-2.23 .001
Histotype A-C/D-K 0.97 0.73-1.31 .87
Systemic symptoms A/B 2.31 0.51-9.12 .27
LDH serum level Normal/elevated 1.41 1.01-2.08 .05
CSF protein level Normal/elevated 1.71 1.03-2.79 .03
No. of lesions Single/multiple 0.98 0.73-1.31 .91
Meningeal disease No/yes 1.28 0.81-2.01 .28
Ocular disease No/yes 0.81 0.45-1.49 .51
Deep lesions No/yes 1.45 1.11-1.91 .007
Planned treatment RT/RT-CHT/CHT/CHT-RT 0.91 0.83-0.99 .05
HD-MTX Yes/no 1.32 1.01-1.89 .05
HD cytarabine Yes/no 1.15 0.78-1.69 .45
Anthracycline Yes/no 1.01 0.68-1.48 .97
Alkylating agents Yes/no 1.27 0.81-2.01 .28
Intrathecal CHT Yes/no 1.21 0.85-1.72 .28
Year of diagnosis Continuous variable 0.99 0.96-1.02 .81
Fig 1. Survival curves for patients grouped according to the proposed prog-
nostic score: patients with 0 to 1 (solid line), 2 to 3 (dotted line), or 4 to 5 (dashed
line) unfavorable features. Analysis was performed on the 105 assessable cases in
which complete data from all 5 variables were available.
Fig 2. Survival curves for patients grouped according to the proposed prog-
nostic score: patients with 0 to 1 (solid line), 2 to 3 (dotted line), or 4 to 5 (dashed
line) unfavorable features. Analysis was performed on the subgroup of 75
assessable patients treated with high-dose methotrexate-based chemotherapy 
radiotherapy.
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deep structures of the brain, and/or meningeal dissemination. In
this series, no correlation between CSF protein level and
involvement of deep structures of the brain was observed. This
feature was reported in 41% of cases with normal CSF protein
levels and 33% of cases with elevated CSF protein levels (P 
.36). Moreover, the distribution of cases with deep tumor
locations was similar in patients with (36%) or without (41%)
lumbar puncture at diagnosis (P  .33). In sum, these data seem
to suggest that CSF protein level may be a measure of tumor
burden and not of the involvement of deep structures of the
brain. On the other hand, the role of CSF protein level as
indicator of meningeal dissemination is unclear. In effect,
elevated CSF protein concentrations are seen in a wide variety of
brain tumors that do not have meningeal involvement. In this
series, no correlation between CSF cytology status and CSF
protein level was observed. In fact, although 90% of cases with
normal CSF protein concentrations were associated with a
negative CSF cytology examination, and 80% of cases with a
positive CSF cytology examination also had an increased CSF
protein concentration, only 22% of cases with increased CSF
protein level had a concomitant positive CSF cytology exami-
nation (2, P  .0000). The well-known high percentage of
false-negatives observed in CSF cytology examination in PC-
NSL21 may explain this situation. In fact, the rate of leptomen-
ingeal seeding is largely underestimated21 because the detection
of lymphomatous cells is sometimes impossible, even in the
presence of extensive meningeal infiltration.22-24
This is the first study reporting an independent prognostic role
of the involvement of deep structures of the brain in PCNSL
patients. In fact, the involvement of periventricular regions, basal
ganglia, brainstem, and/or cerebellum was associated with a poor
prognosis. This feature was previously related to a worse
survival only in univariate analyses,17,19 although a potential
association between involvement of the deep structures of the
brain and a subclinical meningeal dissemination was hypothe-
sized.17 In our experience, the association between the involve-
ment of deep structures of the brain and worse outcome was
independent of the CSF parameters studied.
The combination of the five independent patient- and lympho-
ma-related predictors (ie, age, PS, LDH serum level, CSF protein
concentration, and involvement of deep structures of the brain)
resulted in a prognostic score significantly associated with
survival. Three different risk groups were identified according to
the presence of zero to one, two to three, or four to five
unfavorable predictors, with a 2-year OS rate  SD of 80% 
8%, 48%  7%, and 15%  7% (P  .0000), respectively.
These results were also confirmed when tested exclusively in the
subgroup of patients treated with HD-MTX–based CHT  RT.
The independent role of these five variables and the clinical
relevance of the proposed prognostic score deserve to be
assessed in further studies. A wider use of well-defined prog-
nostic factors will facilitate the critical comparison of reported
therapeutic results, and an established prognostic score may
allow the identification of different risk groups of patients who
perhaps require distinct therapeutic strategies.
APPENDIX
The appendix is available online at www.jco.org.
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